Výsledky vyhledávání - "Oligopeptides/therapeutic use"

Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy

Autor: Matthew L. Albert, Yoann Barthe, Armanda Casrouge, Arnaud Fontanet, Stanislas Pol, Sylvie Lagaye, Hélène Fontaine, Vincent Mallet, Philippe Sultanik, Christophe Hézode, Estelle Mottez, Laurent Abel, Etienne Gayat, Céline Dorival, Fabrice Carrat, Jean-Pierre Bronowicki, Ioannis Theodorou

Publikováno v: Liver International
Liver International, Wiley-Blackwell, 2015, 35 (7), pp.1833-1844. ⟨10.1111/liv.12759⟩
Liver International, 2015, 35 (7), pp.1833-1844. ⟨10.1111/liv.12759⟩
Liver International, Wiley-Blackwell, 2015, 35 (7), pp.1833-1844. 〈10.1111/liv.12759〉

International audience; BACKGROUND & AIMS:Chronic infection with HCV remains a public health problem with approximately 150 million people infected worldwide. HCV intersects with lipid metabolism for replication and entry; and plasma concentrations o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90633f842d8de6ea3f7f4df0ad3c882d
https://doi.org/10.1111/liv.12759

Zobrazit plný text záznamu

Plný text ve formátu HTML

Autor: Carrieri, Maria Patrizia, Protopopescu, Camelia, Younossi, Zobair, Vilotitch, Antoine, Fontaine, Hélène, Petrov-Sanchez, Ventzislava, Marcellin, Fabienne, Carrat, Fabrice, Hézode, Christophe, Bourlière, Marc, Poncin, Eric, Botta-Friedland, Danièle, Fontanges, Thierry, Arpurt, Jean-Pierre, Bacq, Yannicq, Calès, Paul, Delasalle, Patrick, Ouzan, Denis, Nousbaum, Jean-Baptiste, Sylvain, Christine, Ribard, Didier, Gatineau-Sailliant, Gilles, de Montigny-Lenhardt, Stéphanie, Renard, Philippe, Pilette, Christophe, Denis, Jacques, Lascoux-Combe, Caroline, Abel, Laurent, Albert, Matthew, Chazouillères, Olivier, Dubuisson, Jean, Negro, Francesco, Pageaux, Georges-Philippe, Paradis, Valérie, Spire, Bruno, Taburet, Anne-Marie, Trinchet, Jean-Claude, Yazdanpanah, Yazdan, Dufour, Cécilie, Fréhaut, Céline, Pirot, Marion, Lesel, Aurélie, Zahraa, Nathalie, Chau, Frédéric

Publikováno v: The Patient-Patient-Centered Outcomes Research
The Patient-Patient-Centered Outcomes Research, 2017, 10 (5), pp.605-614. ⟨10.1007/s40271-017-0232-1⟩
The Patient-Patient-Centered Outcomes Research, Vol. 10, No 5 (2017) pp. 605-614

International audience; Objective We aimed to compare health-related quality of life (HRQL) during and after HCV treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir - ANRS CO20 CUPIC c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff9a9084dace7c7dc34a62f21b4933e
https://hal.science/hal-01767765/document

Zobrazit plný text záznamu

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study

Autor: Fabrice Carrat, Fabien Zoulim, Dominique Larrey, Lawrence Serfaty, Christophe Hézode, Hélène Fontaine, Jean-Pierre Zarski, Véronique Loustaud-Ratti, François Bailly, Cécilie Dufour, Pierre Pradat, Jean-Pierre Bronowicki, Victor Virlogeux, Marc Bourlière, Sophie Metivier, Laurent Alric, Didier Samuel

Publikováno v: Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, 2015, 39 (4), pp.443-450. ⟨10.1016/j.clinre.2014.12.007⟩
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2015, 39 (4), pp.443-450. ⟨10.1016/j.clinre.2014.12.007⟩

Summary Background and objective To assess within the ANRS CO20-CUPIC cohort whether the viral load (VL) at week 2/week 6 for telaprevir/boceprevir-based triple therapy, respectively, was predictive of sustained virological response (SVR) in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd59c4d123cafb31f116f5e39652393
https://hal.univ-lorraine.fr/hal-01669113

Zobrazit plný text záznamu

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients

Autor: Dominique L Braun, Andri Rauch, Manel Aouri, Nina Durisch, Nadia Eberhard, Alexia Anagnostopoulos, Bruno Ledergerber, Beat Müllhaupt, Karin J Metzner, Laurent Decosterd, Jürg Böni, Rainer Weber, Jan Fehr, Swiss HIV Cohort Study

Publikováno v: PLoS ONE
Plos One, vol. 10, no. 7, pp. e0133028
PLoS ONE, Vol 10, Iss 7, p e0133028 (2015)

Background The efficacy of first-generation protease inhibitor based triple-therapy against hepatitis C virus (HCV) infection is limited in HIV/HCV-coinfected patients with advanced liver fibrosis and non-response to previous peginterferon-ribavirin.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79071fad6229260dd2be161bb970fb2e
https://pubmed.ncbi.nlm.nih.gov/26252715

Zobrazit plný text záznamu

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients

Autor: Boursier, J, Ducancelle, A, Vergniol, J, Veillon, P, Moal, V, Dufour, C, Bronowicki, J-P, Larrey, D, Hézode, C, Zoulim, F, Fontaine, H, Canva, V, Poynard, T, Allam, S, De Lédinghen, V, ANRS CO20-CUPIC study group

Publikováno v: Journal of Viral Hepatitis, Vol. 22, No 12 (2015) pp. 1002-1010
Journal of Viral Hepatitis
Journal of Viral Hepatitis, Wiley-Blackwell, 2015, 22 (12), pp.1002-1010. ⟨10.1111/jvh.12433⟩
Journal of Viral Hepatitis, 2015, 22 (12), pp.1002-1010. ⟨10.1111/jvh.12433⟩

International audience; Triple therapy using boceprevir or telaprevir remains the reference treatment for genotype 1 chronic hepatitis C in countries where new interferon-free regimens have not yet become available. Antiviral treatment is highly requ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf353a058b7a0a651c017df28a668d9
https://archive-ouverte.unige.ch/unige:126404

Zobrazit plný text záznamu

Interventions for treating leg ulcers in people with sickle cell disease

Autor: Jennifer Knight-Madden, Maria José Martinez-Zapata, Arturo J Martí-Carvajal

Publikováno v: The Cochrane Library
Cochrane Database of Systematic Reviews
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Cochrane Database Syst Rev

Background The frequency of skin ulceration makes it an important contributor to the morbidity burden in people with sickle cell disease. Many treatment options are available to the healthcare professional, although it is uncertain which treatments h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c767c638c1e401c994c7d1a223f5e2
https://doi.org/10.1002/14651858.cd008394.pub3

Zobrazit plný text záznamu

Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition

Autor: Anja K. Bosserhoff, Wolfram Gronwald, Burkhard König, Jennifer Schmidt, Alexander Riechers, Raphael Stoll, T. Amann, Florian Fink, Thilo Spruss, Claus Hellerbrand

Publikováno v: PLoS ONE
PLoS ONE, Vol 7, Iss 5, p e37941 (2012)

Melanoma is the most aggressive form of skin cancer, with fast progression and early dissemination mediated by the melanoma inhibitory activity (MIA) protein. Here, we discovered that dimerization of MIA is required for functional activity through mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b1f43c43398b7f705bace38faf9e0e

Zobrazit plný text záznamu

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir

Autor: Swiss Association for the Study of the Liver, Moradpour, D., Helbling, B., Cerny, A., De Gottardi, A., Heim, MH., Majno, P., Müllhaupt, B., Negro, F., Rubbia-Brandt, L., Semela, D., Vilei, SB., Bernsmeier, C., Bihl, F., Borovicka, J., Dill, M., Dufour, JF., Filipowicz, M., Geier, A., Gerlach, T., Giostra, E., Gonvers, JJ., Goossens, N., Gubler, C., Hadengue, A., Hellstern, M., Hirschi, C., Jochum, W., Krähenbühl, S., Kullak-Ublick, G., Lange, C., Lavanchy, D., Malinverni, R., McLin, V., Mentha, G., Mertens, JC., Nasser, S., Oneta, C., Pache, I., Sauter, B., Spahr, L., Steuerwald, M., Stickel, F., Stieger, B., Wehr, K., Zala, G.

Publikováno v: Swiss Medical Weekly, vol. 142, pp. w13516

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::6ee87f41a92e705c347129154dd61036
https://serval.unil.ch/notice/serval:BIB_24285838CE70

Zobrazit plný text záznamu

Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier?

Autor: Goossens, Nicolas, Negro, Francesco

Publikováno v: Revue médicale suisse, Vol. 7, No 307 (2011) pp. 1683-8

The hepatitis C virus (HCV) is a global major health burden, its response to current treatment is unfortunately inadequate, in particular for genotype 1. Two new direct acting antivirals, that inhibit NS3/4A viral protease, will soon be available on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1400::07a069cfb08fd3fa06e4bb24c1cc4d50
https://archive-ouverte.unige.ch/unige:25523

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání